2009, ISBN 9780805858457, xix, 544
This book tackles a subject that has captured the imagination of many researchers in the field: attitudes. Although the field has always recognized that...
Attitude (Psychology) | Psychology
Attitude (Psychology) | Psychology
Book
The Times Educational Supplement, ISSN 0040-7887, 06/2012, Issue 4995, p. 46
Trade Publication Article
Journal of Heart and Lung Transplantation, ISSN 1053-2498, 2013, Volume 32, Issue 2, pp. 157 - 187
Institutional Affiliations Co-chairs Feldman D: Minneapolis Heart Institute, Minneapolis, Minnesota, Georgia Institute of Technology and Morehouse School of...
Surgery | SURGERY | CARDIAC & CARDIOVASCULAR SYSTEMS | VENTRICULAR-ASSIST-DEVICE | ARTERY-BYPASS-SURGERY | EXERCISE OXYGEN-CONSUMPTION | HEPARIN-INDUCED THROMBOCYTOPENIA | FIXED PULMONARY-HYPERTENSION | VON-WILLEBRAND-SYNDROME | TRANSPLANTATION | ACC/AHA/ESC 2006 GUIDELINES | RECEIVING CONTINUOUS-FLOW | RESPIRATORY SYSTEM | QUALITY-OF-LIFE | CRITICALLY-ILL PATIENTS | Heart Failure - complications | Assisted Circulation - instrumentation | Risk Assessment | Humans | Contraindications | Patient Selection | Heart Failure - therapy | Societies, Medical | Heart Valve Diseases - complications | Myocardial Ischemia - complications | Quality of Life | Endocarditis - complications | Heart-Lung Transplantation - standards | Patient Education as Topic | Transplantation of organs, tissues, etc
Surgery | SURGERY | CARDIAC & CARDIOVASCULAR SYSTEMS | VENTRICULAR-ASSIST-DEVICE | ARTERY-BYPASS-SURGERY | EXERCISE OXYGEN-CONSUMPTION | HEPARIN-INDUCED THROMBOCYTOPENIA | FIXED PULMONARY-HYPERTENSION | VON-WILLEBRAND-SYNDROME | TRANSPLANTATION | ACC/AHA/ESC 2006 GUIDELINES | RECEIVING CONTINUOUS-FLOW | RESPIRATORY SYSTEM | QUALITY-OF-LIFE | CRITICALLY-ILL PATIENTS | Heart Failure - complications | Assisted Circulation - instrumentation | Risk Assessment | Humans | Contraindications | Patient Selection | Heart Failure - therapy | Societies, Medical | Heart Valve Diseases - complications | Myocardial Ischemia - complications | Quality of Life | Endocarditis - complications | Heart-Lung Transplantation - standards | Patient Education as Topic | Transplantation of organs, tissues, etc
Journal Article
Journal of Heart and Lung Transplantation, ISSN 1053-2498, 2010, Volume 29, Issue 4, pp. S1 - S39
Continuous-flow left ventricular assist devices (LVAD) have emerged as the standard of care for advanced heart failure patients requiring long-term mechanical...
Surgery | patient and device management | destination therapy | bridge to transplantation | mechanical circulatory support | assisted circulation | patient selection | LVAD | SURGERY | CARDIAC & CARDIOVASCULAR SYSTEMS | RISK-FACTORS | RENAL-FUNCTION | BRIDGE | TRANSPLANTATION | INHALED PROSTAGLANDIN | SCREENING SCALE | PULMONARY VASODILATOR | RESPIRATORY SYSTEM | AORTIC-INSUFFICIENCY | PREDICT SURVIVAL | ADVERSE EVENTS | Heart Failure - therapy | Risk Assessment | Humans | Clinical Trials as Topic | Heart-Assist Devices - adverse effects | Preoperative Care | Patient Selection
Surgery | patient and device management | destination therapy | bridge to transplantation | mechanical circulatory support | assisted circulation | patient selection | LVAD | SURGERY | CARDIAC & CARDIOVASCULAR SYSTEMS | RISK-FACTORS | RENAL-FUNCTION | BRIDGE | TRANSPLANTATION | INHALED PROSTAGLANDIN | SCREENING SCALE | PULMONARY VASODILATOR | RESPIRATORY SYSTEM | AORTIC-INSUFFICIENCY | PREDICT SURVIVAL | ADVERSE EVENTS | Heart Failure - therapy | Risk Assessment | Humans | Clinical Trials as Topic | Heart-Assist Devices - adverse effects | Preoperative Care | Patient Selection
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2014, Volume 15, Issue 8, pp. 894 - 904
Summary Background Evidence is scarce for the effectiveness of therapies for oesophageal cancer progressing after chemotherapy, and no randomised trials have...
Hematology, Oncology and Palliative Medicine | GROWTH-FACTOR RECEPTOR | LUNG-CANCER | CETUXIMAB | ONCOLOGY | GASTRIC-CANCER | ADENOCARCINOMAS | SQUAMOUS-CELL CARCINOMA | ADVANCED ESOPHAGOGASTRIC CANCER | QUALITY-OF-LIFE | II TRIAL | ADVANCED COLORECTAL-CANCER | Humans | Middle Aged | Male | Antineoplastic Agents - therapeutic use | Fatigue - chemically induced | Diarrhea - chemically induced | Esophageal Neoplasms - complications | Antineoplastic Agents - adverse effects | Pain - etiology | Deglutition Disorders - etiology | Female | Drug Eruptions - etiology | Eating | Double-Blind Method | Proportional Hazards Models | Adenocarcinoma - drug therapy | Adenocarcinoma - complications | Disease Progression | Disease-Free Survival | Retreatment | Carcinoma, Squamous Cell - drug therapy | Quinazolines - therapeutic use | Carcinoma, Squamous Cell - complications | Quinazolines - adverse effects | Quality of Life | Aged | Esophageal Neoplasms - drug therapy | Clinical trials | Chemotherapy | Hospitals | Gefitinib | Esophageal cancer | Cancer
Hematology, Oncology and Palliative Medicine | GROWTH-FACTOR RECEPTOR | LUNG-CANCER | CETUXIMAB | ONCOLOGY | GASTRIC-CANCER | ADENOCARCINOMAS | SQUAMOUS-CELL CARCINOMA | ADVANCED ESOPHAGOGASTRIC CANCER | QUALITY-OF-LIFE | II TRIAL | ADVANCED COLORECTAL-CANCER | Humans | Middle Aged | Male | Antineoplastic Agents - therapeutic use | Fatigue - chemically induced | Diarrhea - chemically induced | Esophageal Neoplasms - complications | Antineoplastic Agents - adverse effects | Pain - etiology | Deglutition Disorders - etiology | Female | Drug Eruptions - etiology | Eating | Double-Blind Method | Proportional Hazards Models | Adenocarcinoma - drug therapy | Adenocarcinoma - complications | Disease Progression | Disease-Free Survival | Retreatment | Carcinoma, Squamous Cell - drug therapy | Quinazolines - therapeutic use | Carcinoma, Squamous Cell - complications | Quinazolines - adverse effects | Quality of Life | Aged | Esophageal Neoplasms - drug therapy | Clinical trials | Chemotherapy | Hospitals | Gefitinib | Esophageal cancer | Cancer
Journal Article
2008, Key readings in social psychology, ISBN 9781841690100, xviii, 491
Book
Gut, ISSN 0017-5749, 02/2017, Volume 66, Issue 2, pp. 210 - 211
 Non-coding RNAs (ncRNAs) are cellular RNA transcripts which can be further subdivided into distinct classes based on their overall length. 7 The most well...
GASTROENTEROLOGY & HEPATOLOGY | CANCER | Carcinoma, Squamous Cell | Prognosis | Esophageal Neoplasms | Humans | Esophageal Squamous Cell Carcinoma | Chemotherapy | Pathogenesis | Genes | Surgery | Medical prognosis | Genomes | Mutation | Cancer therapies | Patients | Cancer
GASTROENTEROLOGY & HEPATOLOGY | CANCER | Carcinoma, Squamous Cell | Prognosis | Esophageal Neoplasms | Humans | Esophageal Squamous Cell Carcinoma | Chemotherapy | Pathogenesis | Genes | Surgery | Medical prognosis | Genomes | Mutation | Cancer therapies | Patients | Cancer
Journal Article
The Lancet, ISSN 0140-6736, 07/2018, Volume 392, Issue 10142, pp. 97 - 98
Anti-PD-1 therapy has been shown to be associated with modest response rates and an improvement in overall survival in chemorefractory gastro-oesophageal...
PHASE-3 TRIAL | DOUBLE-BLIND | MEDICINE, GENERAL & INTERNAL | MELANOMA | NIVOLUMAB | IPILIMUMAB | Adenocarcinoma | Statistical analysis | Microsatellites | Stability | Melanoma | Antibodies | Hazards | Cancer therapies | Survival | Esophagus | Skin cancer | Chemotherapy | Pembrolizumab | Immunotherapy | Paclitaxel | Biomarkers | Mutation | Combinatorial analysis | Tumors | Cancer
PHASE-3 TRIAL | DOUBLE-BLIND | MEDICINE, GENERAL & INTERNAL | MELANOMA | NIVOLUMAB | IPILIMUMAB | Adenocarcinoma | Statistical analysis | Microsatellites | Stability | Melanoma | Antibodies | Hazards | Cancer therapies | Survival | Esophagus | Skin cancer | Chemotherapy | Pembrolizumab | Immunotherapy | Paclitaxel | Biomarkers | Mutation | Combinatorial analysis | Tumors | Cancer
Journal Article
Ophthalmology, ISSN 0161-6420, 2015, Volume 122, Issue 9, pp. 1846 - 1853.e5
Purpose To evaluate the association of subretinal hyperreflective material (SHRM) with visual acuity (VA), geographic atrophy (GA), and scar in the Comparison...
Ophthalmology | OPHTHALMOLOGY | PHOTORECEPTOR LAYER | RISK | VISUAL-ACUITY LOSS | RANIBIZUMAB | Antibodies, Monoclonal, Humanized - therapeutic use | Prospective Studies | Intravitreal Injections | Tomography, Optical Coherence | Humans | Middle Aged | Geographic Atrophy - physiopathology | Cicatrix - diagnosis | Vascular Endothelial Growth Factor A - antagonists & inhibitors | Bevacizumab | Retinal Pigment Epithelium | Wet Macular Degeneration - drug therapy | Ranibizumab | Angiogenesis Inhibitors - therapeutic use | Retina - pathology | Visual Acuity - physiology | Fluorescein Angiography | Macular degeneration | Clinical trials | Physiological aspects | Comparative analysis | Drug therapy
Ophthalmology | OPHTHALMOLOGY | PHOTORECEPTOR LAYER | RISK | VISUAL-ACUITY LOSS | RANIBIZUMAB | Antibodies, Monoclonal, Humanized - therapeutic use | Prospective Studies | Intravitreal Injections | Tomography, Optical Coherence | Humans | Middle Aged | Geographic Atrophy - physiopathology | Cicatrix - diagnosis | Vascular Endothelial Growth Factor A - antagonists & inhibitors | Bevacizumab | Retinal Pigment Epithelium | Wet Macular Degeneration - drug therapy | Ranibizumab | Angiogenesis Inhibitors - therapeutic use | Retina - pathology | Visual Acuity - physiology | Fluorescein Angiography | Macular degeneration | Clinical trials | Physiological aspects | Comparative analysis | Drug therapy
Journal Article